Rare Cancer News & Clinical Trials » Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma (83 unread)

Google - Adenoid Cystic Carcinoma

KU alumna's outlook on life a positive influence she left behind - Lawrence Journal World

Posted: September 1st, 2010, 4:17am CDT

KU alumna's outlook on life a positive influence she left behind
Lawrence Journal World
She had battled adenoid cystic carcinoma, all the while striving to make the world around her a better place. By Andy Hyland When Stan Loeb tells people ...

KU grad left legacy of courage - University Daily Kansan

Posted: August 31st, 2010, 5:31pm CDT

KU grad left legacy of courage
University Daily Kansan
Roark was diagnosed with Adenoid Cystic Carcinoma during her sophomore year at the University. The cancer occurs in salivary glands, but can appear anywhere ...

Radiation After Surgery Improves Survival for Rare Type of Breast Cancer - HealthNewsDigest.com

Posted: August 31st, 2010, 10:57am CDT

Radiation After Surgery Improves Survival for Rare Type of Breast Cancer
HealthNewsDigest.com
Adenoid cystic carcinoma, a tumor type that represents less than 1 percent of all breast carcinomas, is generally treated with surgery alone — either ...

and more »

Adenoid cystic carcinoma of the peripheral lung: a case report - 7thSpace Interactive (press release)

Posted: August 26th, 2010, 6:57am CDT

Adenoid cystic carcinoma of the peripheral lung: a case report
7thSpace Interactive (press release)
Adenoid cystic carcinoma of the peripheral lung is a rare entity. We recently encountered a patient with adenoid cystic carcinoma. ...

Pathology Quiz Case 1: Diagnosis - Archives of Otolaryngology

Posted: August 16th, 2010, 1:23pm CDT

Pathology Quiz Case 1: Diagnosis
Archives of Otolaryngology
... nasopharyngeal mass should include squamous cell carcinoma and histologic variants, nasopharyngeal carcinoma, adenocarcinoma, adenoid cystic carcinoma, ...

Tork and Blue Suede Shoes at Skylands - Sparta Independent

Posted: August 16th, 2010, 11:24pm CDT

Sparta Independent

Tork and Blue Suede Shoes at Skylands
Sparta Independent
... his life turned upside down after being diagnosed a couple of years ago with adenoid cystic carcinoma, a rare slow growing form of head and neck cancer. ...

Tork and Blue Suede Shoes at Skylands - Township Journal

Posted: August 13th, 2010, 11:21pm CDT

Township Journal

Tork and Blue Suede Shoes at Skylands
Township Journal
... his life turned upside down after being diagnosed a couple of years ago with adenoid cystic carcinoma, a rare slow growing form of head and neck cancer. ...

Unlikely Friends Find Bond In Cancer Battle, Firefighting - NBC Philadelphia

Posted: July 28th, 2010, 10:42pm CDT

Unlikely Friends Find Bond In Cancer Battle, Firefighting
NBC Philadelphia
He was also undergoing treatment for a rare cancer called Adenoid Cystic Carcinoma. And it wasn't long before the teen and ex-marine leaned on each other as ...

and more »

Adenoid cystic carcinoma of the breast in the United States (1977-2006): a ... - 7thSpace Interactive (press release)

Posted: July 23rd, 2010, 12:45pm CDT

Adenoid cystic carcinoma of the breast in the United States (1977-2006): a ...
7thSpace Interactive (press release)
IntroductionAdenoid cystic carcinoma of the breast (breast-ACC) is a rare and special type of basal-like tumor for which scant population-based descriptive ...

Cancer overcome, next hurdle is triathlon - The Riverdale Press

Posted: July 14th, 2010, 12:21pm CDT

The Riverdale Press

Cancer overcome, next hurdle is triathlon
The Riverdale Press
Although Bakst had no symptoms, further tests confirmed that Bakst had a rare form of cancer — adenoid cystic carcinoma — that afflicts fewer than 1000 ...

Pleural Mesothelioma One of Few Thoracic Cancers to Spontaneously Regress - Asbestos.com

Posted: July 7th, 2010, 12:17pm CDT

Pleural Mesothelioma One of Few Thoracic Cancers to Spontaneously Regress
Asbestos.com
Of the five cases, two were pleural mesothelioma, two were primary lung cancer (squamous cell) and one was adenoid cystic carcinoma. ...

Local cancer survivor stays focused on her life, not fear - Williston Daily Herald

Posted: July 3rd, 2010, 5:10pm CDT

Williston Daily Herald

Local cancer survivor stays focused on her life, not fear
Williston Daily Herald
But it was a cancer called adenoid cystic carcinoma. Lee was shocked. "It kinda hits you weird, 'cause you're not sick," she said. ...

and more »

The 2010 Sunday Mercury Wonderkids - Sunday Mercury

Posted: July 3rd, 2010, 9:53am CDT

The 2010 Sunday Mercury Wonderkids
Sunday Mercury
Ellis had adenoid cystic carcinoma – cancer in his neck which had spread across his face. He underwent operations and radiotherapy and was given the ...

Couple Raises $3M To Fight Rare Cancer - WCVB-TV

Posted: June 28th, 2010, 10:32am CDT

Couple Raises $3M To Fight Rare Cancer
WCVB-TV
BOSTON -- Marnie and Jeff Kaufman had four boys under 10 when the Needham woman was diagnosed with adenoid cystic carcinoma in 2004. She was 38 years old. ...

and more »

Tumour dad's charity bike ride - The Star

Posted: June 28th, 2010, 3:52am CDT

Tumour dad's charity bike ride
The Star
Dan Porter, aged 36, had just become a father for the first time when he was diagnosed with adenoid cystic carcinoma - a rare form of cancer which resulted ...
Rare cancer spurs Mokena family to action - Chicago Tribune

Posted: June 25th, 2010, 12:03am CDT

Rare cancer spurs Mokena family to action
Chicago Tribune
Alicia Almanza, 37, has lived with adenoid cystic carcinoma since the age of 18. The rare, slow-growing cancer ...

Cutaneous appendageal carcinomas increased 150% in United States since 1978 - HemOncToday

Posted: June 22nd, 2010, 5:40am CDT

Cutaneous appendageal carcinomas increased 150% in United States since 1978
HemOncToday
According to background data, only 62 cases of spiradenocarcinoma and adenoid cystic carcinoma and less than 100 cases of most other apocrine-eccrine ...

and more »

Gophers runner endures cancer surgery, then thrives - Big Ten Network

Posted: June 16th, 2010, 10:04am CDT

Gophers runner endures cancer surgery, then thrives
Big Ten Network
Anderson's 2009 outdoor season ended abruptly after she was diagnosed with adenoid cystic carcinoma, a rare cancer. She had surgery to remove a tumor from ...

Pushed to be her best - Minneapolis Star Tribune

Posted: June 14th, 2010, 8:55pm CDT

Pushed to be her best
Minneapolis Star Tribune
Anderson's 2009 outdoor season ended abruptly after she was diagnosed with adenoid cystic carcinoma, a rare cancer. She had surgery to remove a tumor from ...

and more »

Trial - Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy

Posted: August 30th, 2010, 9:00am CDT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: cetuximab weekly
Sponsors: University of Heidelberg; Dept. of Radiation Oncology, INF 400, 69120 Heidelberg, Germany; Heidelberg Ion Therapy Center (HIT), INF 450, 69120 Heidelberg, Germany; Merck KGaA
Not yet recruiting - verified August 2010
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

Posted: August 4th, 2010, 9:00am CDT

Condition: Head and Neck Cancer
Interventions: Drug: vorinostat; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified August 2010
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

Posted: July 28th, 2010, 9:00am CDT

Conditions: Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer
Interventions: Drug: docetaxel; Drug: pemetrexed disodium
Sponsors: University of Arizona; National Cancer Institute (NCI)
Recruiting - verified July 2010
Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy

Posted: July 7th, 2010, 9:00am CDT

Conditions: Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Procedure: endoscopic procedure; Other: questionnaire administration
Sponsor: Wake Forest University
Not yet recruiting - verified June 2010
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Posted: July 1st, 2010, 9:00am CDT

Conditions: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain
Interventions: Drug: doxepin hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Not yet recruiting - verified June 2010
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer

Posted: June 29th, 2010, 9:00am CDT

Conditions: Mucositis; Oral Complications of Chemotherapy; Oral Complications of Radiation Therapy; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Basal Cell Carcinoma of the Lip; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Salivary Gland Cancer; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Basal Cell Carcinoma of the Lip; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Salivary Gland Cancer; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Procedure: quality-of-life assessment; Procedure: management of therapy complications; Dietary Supplement: L-lysine
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified June 2010
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Posted: March 30th, 2010, 9:00am CDT

Conditions: Breast Cancer; Cardiovascular Complications; Colorectal Cancer; Fallopian Tube Cancer; Head and Neck Cancer; Lung Cancer; Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck

Posted: February 8th, 2010, 9:00am CST

Conditions: Carcinoma, Adenoid Cystic; Head and Neck Neoplasms
Intervention: Drug: Nelfinavir
Sponsors: University of Iowa; Holden Comprehensive Cancer Center
Recruiting - verified August 2010
Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer

Posted: September 5th, 2009, 9:00am CDT

Condition: Head and Neck Cancer
Interventions: Other: questionnaire administration; Radiation: 3-dimensional conformal radiation therapy; Radiation: radiation therapy treatment planning/simulation
Sponsor: All Ireland Cooperative Oncology Research Group
Active, not recruiting - verified July 2010
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Posted: May 9th, 2009, 9:00am CDT

Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Radiation: radiation therapy
Sponsor: Vanderbilt-Ingram Cancer Center
Completed - verified July 2010
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer

Posted: May 9th, 2009, 9:00am CDT

Condition: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified July 2010
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Posted: March 10th, 2009, 9:00am CDT

Condition: Head and Neck Cancer
Interventions: Drug: dasatinib; Genetic: gene expression analysis; Genetic: gene rearrangement analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified July 2010
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

Posted: December 19th, 2007, 9:00am CST

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: doxorubicin and bortezomib
Sponsors: University of Pittsburgh; Millennium Pharmaceuticals, Inc.
Active, not recruiting - verified August 2010
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Posted: October 1st, 2007, 9:00am CDT

Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Posted: July 10th, 2007, 9:00am CDT

Condition: Cancer
Interventions: Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: cryosurgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Posted: November 8th, 2006, 9:00am CST

Condition: Cancer
Interventions: Biological: cetuximab; Drug: erlotinib hydrochloride; Genetic: proteomic profiling; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2009
NGR-TNF in Treating Patients With Advanced Solid Tumors

Posted: December 8th, 2004, 9:00am CST

Conditions: Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: CNGRC peptide-TNF alpha conjugate
Sponsor: European Organization for Research and Treatment of Cancer
Active, not recruiting - verified October 2007
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Posted: November 12th, 2002, 9:00am CST

Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified June 2010
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Posted: September 13th, 2001, 9:00am CDT

Conditions: Breast Cancer; Head and Neck Cancer; Lymphoma; Metastatic Cancer; Non-melanomatous Skin Cancer; Sarcoma
Intervention: Drug: silicon phthalocyanine 4
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Terminated - verified June 2010
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Posted: May 2nd, 2000, 9:00am CDT

Condition: Head and Neck Cancer
Interventions: Drug: paclitaxel; Drug: semaxanib
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified June 2010

PubMed - Adenoid Cystic Carcinoma

Adenoid cystic carcinoma of the peripheral lung: a case report.

Fetched: September 1st, 2010, 9:30am CDT

Related Articles

Adenoid cystic carcinoma of the peripheral lung: a case report.

World J Surg Oncol. 2010 Aug 26;8(1):74

Authors: Kitada M, Ozawa K, Sato K, Hayashi S, Tokusashi Y, Miyokawa N, Sasajima T

ABSTRACT: Adenoid cystic carcinoma of the peripheral lung is a rare entity. We recently encountered a patient with adenoid cystic carcinoma. A 75-year-old woman showed a nodular lesion with 10mm in diameter in the right upper lung field on chest radiography. The diagnosis was unclear, but lung cancer could not be ruled out. Thoracoscopic biopsy was performed, and intraoperative pathological diagnosis revealed the carcinoma of the lung. We enforced upper lobectomy and mediastinal lymph node dissection to the patient. Histopathological examination revealed adenoid cystic carcinoma with a characteristic cribriform structure. Immunohistochemical examination revealed that the tumor cells were positive for thyroid transcription factor 1 (TTF-1), this tumor was diagnosed primary ACC of the lung.

PMID: 20796281 [PubMed - as supplied by publisher]
Expression and importance of zinc-finger transcription factor Slug in adenoid cystic carcinoma of salivary gland.

Fetched: September 1st, 2010, 9:30am CDT

Related Articles

Expression and importance of zinc-finger transcription factor Slug in adenoid cystic carcinoma of salivary gland.

J Oral Pathol Med. 2010 Aug 3;

Authors: Tang Y, Liang X, Zhu G, Zheng M, Yang J, Chen Y

Background: It has been reported that zinc-finger transcription factor Slug plays a critical role in tumor proliferation and differentiation, relapse, invasion, metastasis, and decreased survival. However, there is little information on the expression and role of Slug in salivary adenoid cystic carcinoma (ACC). Method: Demographic variables and primary tumor site, dates of diagnoses, perineural invasion, local regional recurrence, and distant metastasis of 121 cases of salivary ACC treated at the Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University between 1996 and 2005 were retrieved. The Slug expression of all these cases was examined by immunohistochemical methods. The association between Slug expression and clinicopathological variables was analyzed using Chi-squared test, and the prognostic factors were examined by univariate and multivariate analyses. Results: Our data demonstrated that the positive expression of Slug was observed in 71.90% (87/121) of cases. Slug expression was significantly associated with tumor site, TNM stage, histological pattern, perineural invasion, local regional recurrence and distant metastasis of patients with ACC (P < 0.05). And Slug expression, local regional recurrence and distant metastasis were independent and significant prognostic factors in all patients. Conclusions: It is proposed that Slug may play an important role in the invasion and metastasis of ACC, and that Slug had the potential for one of the strong invasion and metastasis indicators at presentation of ACC patients.

PMID: 20738754 [PubMed - as supplied by publisher]
Beyond triple-negative breast cancer: the need to define new subtypes.

Fetched: September 1st, 2010, 9:30am CDT

Related Articles

Beyond triple-negative breast cancer: the need to define new subtypes.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1197-213

Authors: Constantinidou A, Jones RL, Reis-Filho JS

Advances in the systemic treatment of early breast cancer have led to significant improvements in survival for patients with hormone receptor- and/or HER2-positive disease. In recent years, interest has focused on tumors that lack expression of the estrogen receptor, progesterone receptor and HER2, the so-called triple-negative subgroup. As a group, triple-negative cancers have a relatively aggressive clinical course, with early development of visceral metastases and a poor long-term prognosis. These tumors, however, encompass a wide range of subtypes with varying prognosis, including a number of special types with a good prognosis (e.g., adenoid cystic carcinomas and secretory carcinoma). There is considerable overlap between triple-negative and basal-like tumors; however, microarray studies have demonstrated that the overlap between basal-like and triple-negative cancers is not complete. The similarities between sporadic triple-negative cancers and tumors arising in BRCA1 mutation carriers and the fact that the majority of BRCA1 tumors display a triple-negative phenotype have led to studies demonstrating a potential loss of BRCA1 function in triple-negative cancers and offered potential therapeutic avenues for patients with these cancers. However, it should be noted that triple-negative breast cancers comprise a heterogeneous group of tumors. Understanding the molecular underpinning of distinct subgroups of these cancers is crucial for the identification of novel therapeutic targets and individualization of treatment for patients with triple-negative disease.

PMID: 20735307 [PubMed - in process]
[Combined chemotherapy with Cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma.]

Fetched: September 1st, 2010, 9:30am CDT

Related Articles

[Combined chemotherapy with Cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma.]

Gan To Kagaku Ryoho. 2010 Aug;37(8):1545-8

Authors: Yamada T, Mouri H, Izumi K, Takeuchi S, Ohtsubo K, Yamashita K, Yasumoto K, Kitamura S, Yano S

We report a case of a 65-year-old man with metastatic primary cutaneous adenoid cystic carcinoma that was effectively treated by combination chemotherapy with cisplatin(CDDP)plus vinorelbine(VNR). He detected a tumor mass on the anterior surface of his left patella in 2003 and underwent a tumorectomy in October 2008. He was given a diagnosis of primary cutaneous adenoid cystic carcinoma with metastatic lesions to multiple lungs and left tibial bone and then given chemotherapy combining CDDP plus VNR as the first treatment in December 2008. By this treatment for six cycles, the lung metastatic tumors gradually reduced on chest CT. We reported the efficacy of combined treatment with CDDP plus VNR for primary cutaneous adenoid cystic carcinoma, because this clinical condition was very rare and the standard treatment has still not been established.

PMID: 20716883 [PubMed - in process]
Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability and Clinicopathological Significance.

Fetched: August 13th, 2010, 9:16pm CDT

Related Articles

Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability and Clinicopathological Significance.

Clin Cancer Res. 2010 Aug 11;

Authors: Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, Weber RS, Caulin C, El-Naggar AK

PURPOSE: The objective of this study was to determine the incidence of the MYB-MFIB fusion in salivary adenoid cystic carcinoma (ACC), to establish the clinicopathological significance of the fusion and to analyze the expression of MYB in ACCs in the context of the MYB-NFIB fusion.EXPERIMENTAL DESIGN: We performed an extensive analysis involving 123 cancers of the salivary gland, including primary and metastatic ACCs, and non-ACC salivary carcinomas. MYB-NFIB fusions were identified by reverse transcription-PCR (RT-PCR) and sequencing of the RT-PCR products, and confirmed by fluorescence in situ hybridization. MYB RNA expression was determined by quantitative RT-PCR and protein expression was analyzed by immunohistochemistry.RESULTS: The MYB-NFIB fusion was detected in 28% primary and 35% metastatic ACCs, but not in any of the non-ACC salivary carcinomas analyzed. Different exons in both MYB and NFIB genes were involved in the fusions, resulting in expression of multiple chimeric variants. Notably, MYB was overexpressed in the vast majority of the ACCs, although MYB expression was significantly higher in tumors carrying the MYB-NFIB fusion. The presence of the MYB-NFIB fusion was significantly associated (p = 0.03) with patients older than 50 years of age. No correlation with other clinicopathological markers, factors and survival was found. CONCLUSIONS: We conclude that the MYB-NFIB fusion characterizes a subset of ACCs and contributes to MYB overexpression. Additional mechanisms may be involved in MYB overexpression in ACCs lacking the MYB-NFIB fusion. These findings suggest that MYB may be a specific novel target for tumor intervention in patients with ACC.

PMID: 20702610 [PubMed - as supplied by publisher]
Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67.

Fetched: August 13th, 2010, 9:16pm CDT

Related Articles

Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67.

Anal Quant Cytol Histol. 2009 Oct;31(5):280-7

Authors: Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA

OBJECTIVE: To analyze the expression of ErbB-1 (Her-1 or EGFR), ErbB-2 (Her-2 or neu), ErbB-3 (Her-3) and ErbB-4 (Her-4) and their correlation in 3 different types of salivary gland tumors. STUDY DESIGN: Immunohistochemical expression of epidermal growth factor (EGF), EGFR, ErbB-2, fatty acid synthase (FAS) and Ki-67 were analyzed in 41 pleomorphic adenoma (PA), in 30 mucoepidermoid carcinoma (MEC) and in 30 adenoid cystic carcinoma (ACC) and correlated with their histologic patterns. RESULTS: EGF was more common in MEC and PA, but MEC had a higher percentage of strongly positive cases. EGFRc and EGFRm were both more frequent in MEC and ACC. Higher scores of ErbB-2c were observed in PA, followed by MEC and ACC. In contrast, higher scores of ErbB-2m were more common in MEC as compared to ACC and PA. FAS was most commonly found in PA and MEC. Moreover, MEC showed the highest percentage of strongly positive cases. Ki-67 was higher in MEC and ACC than in PA. From a correlation of immunomarkers with the histologic patterns, it was observed that cribriform ACC presented more expression of EGFR and high grade MEC showed a higher percentage of ErbB-2, FAS and Ki-67. CONCLUSION: EGF, EGFR, ErbB-2 and FAS were commonly found and seem to be important in the tumorigenesis of salivary gland tumors, particularly in percentage of strongly positive cases. Ki-67 was higher in MEC and ACC than in PA. From a correlation of immunomarkers with the histologic patterns, it was observed that cribriform ACC presented more expression of EGFR and high grade MEC showed a higher percentage of ErbB-2, FAS and Ki-67. CONCLUSION: EGF, EGFR, ErbB-2 and FAS were commonly found and seem to be important in the tumorigenesis of salivary gland tumors, particularly in MEC. (Anal Quant Cytol Histol 2009;31:280-287)

PMID: 20701095 [PubMed - in process]
A balanced perspective for management of tracheal salivary gland-type carcinomas.

Fetched: August 13th, 2010, 9:16pm CDT

Related Articles

A balanced perspective for management of tracheal salivary gland-type carcinomas.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):394

Authors: Denlinger CE

PMID: 20637918 [PubMed - indexed for MEDLINE]
Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma.

Fetched: August 10th, 2010, 6:31pm CDT

Related Articles

Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma.

Int J Oral Sci. 2010 Mar;2(1):35-44

Authors: Hao L, Xiao-lin N, Qi C, Yi-ping Y, Jia-quan L, Yan-ning L

AIM: To detect the expression of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) in salivary adenoid cystic carcinoma (SACC) tissues, as well as to determine the correlation between growth factor expression and prognosis in SACC. METHODOLOGY: Medical records of 63 patients surgically treated for SACC between January 1988 and October 2005 were reviewed. Immunohistochemistry was performed to examine the expression of NGF and VEGF in tumor tissues. Kaplan-Meier analysis and Cox's proportional hazard regression model were applied to assess predictors of survival. RESULTS: NGF and VEGF were overexpressed in SACC tissues, compared with those in normal salivary tissues (P < 0.05), and the staining intensity of these two factors was stronger in groups of solid subtype, advanced TNM stage, perineural invasion and recurrence. Patients with high-expression of NGF and VEGF, solid subtype, advanced stage, perineural invasion, recurrence and extended resection alone had worse survival rates (P < 0.05). CONCLUSION: NGF and VEGF are expressed increasingly in the tissues of SACC cases with invasion and metastasis. NGF expression and VEGF expression are independent

PMID: 20690417 [PubMed - in process]
Adenoid cystic carcinomas of the breast have low topoisomerase IIalpha expression but frequently overexpress epidermal growth factor protein without epidermal growth factor gene amplification.

Fetched: August 10th, 2010, 6:31pm CDT

Related Articles

Adenoid cystic carcinomas of the breast have low topoisomerase IIalpha expression but frequently overexpress epidermal growth factor protein without epidermal growth factor gene amplification.

Hum Pathol. 2010 Aug 3;

Authors: Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z

Adenoid cystic carcinoma of the breast is a rare subtype of breast cancer with basal-like features. Published studies on breast adenoid cystic carcinoma are limited, resulting in relatively scarce information on the value of predictive tumor markers. We studied 20 primary cases of adenoid cystic carcinoma of the breast for expression of estrogen receptor, progesterone receptor, androgen receptor, epidermal growth factor receptor, HER-2/neu, and topoisomerase IIalpha using immunohistochemistry and fluorescent in situ hybridization methods. Estrogen and progesterone receptor expression were detected in 1 case each. All tumors were uniformly negative for Her-2/neu expression. Androgen receptor and topoisomerase IIalpha expression were weakly positive in three cases and 7 cases, respectively. Epidermal growth factor receptor overexpression was detected in 13 cases (65% of all cases). Amplification of TOP2A or HER-2/neu gene was not detected in any of the cases. Our study shows that the majority of adenoid cystic carcinomas of the breast do not overexpress Her-2/neu, topoisomerase IIalpha, or estrogen receptor, and thus, they are unlikely to respond to therapies targeting these proteins. However, these tumors frequently over-express epidermal growth factor receptor, indicating a potential benefit from anti-epidermal growth factor receptor therapy for patients with advanced adenoid cystic carcinomas of the breast.

PMID: 20688355 [PubMed - as supplied by publisher]
[Diagnosis and treatment of tracheal or bronchuotracheal adenoid cystic carcinoma]

Fetched: August 10th, 2010, 6:31pm CDT

Related Articles

[Diagnosis and treatment of tracheal or bronchuotracheal adenoid cystic carcinoma]

Zhongguo Fei Ai Za Zhi. 2010 Jun;13(6):628-31

Authors: Qin M, Fu Y, Yu D, Xu S, Han M, Wang Z

BACKGROUND AND OBJECTIVE: Adenoid cystic carcinoma is primary bronchopulmonary carcinoma with low malignancy, and 43 patients treated in the past 50 years in our hospital were retrospectively studied. The aim of this study is to discuss the clinical symptoms, pathologic characteristic and therapeutic method of primary tracheal or bronchuotracheal adenoid cystic carcinoma. METHODS: This study summarized total 43 patients of primary tracheal or bronchus adenoid cystic carcinoma treated in our hospital from Jan. 1958 to Dec. 2007. Among them, 40 patients were treated by surgical resection, and 3 patients were treated by fiberoptic bronchoscope's interventional treatment. RESULTS: The 1-yr, 3-yr, 5-yr survival rates of the 43 patients above were 100% (41/41), 89.5% (34/38), 87.1% (27/31), respectively. CONCLUSION: Primary tracheal or bronchus adenoid cystic carcinoma are rare and low malignancy carcinoma. The clinical symptoms of them are not typical. The best treatment is early detection and taking measures of operation plus radiotherapy. The other palliative treatment is fiberoptic bronchoscope's interventional treatment.

PMID: 20681452 [PubMed - in process]
Signaling pathways in adenoid cystic cancers: implications for treatment.

Fetched: August 10th, 2010, 6:31pm CDT

Related Articles

Signaling pathways in adenoid cystic cancers: implications for treatment.

Cancer Biol Ther. 2009 Oct;8(20):1947-51

Authors: Gupta AK, Wilke WW, Taylor EN, Bodeker KL, Hoffman HT, Milhem MM, Buatti JM, Robinson RA

Adenoid cystic cancers (ACC) in the head and neck are rare yet present a clinical dilemma. Although 5-y survivals are excellent, they have a propensity for late recurrences. Most of these cancers are initially treated with surgery followed by radiation. When recurrences happen, treatment options are limited both by the morbidity and low efficacy of re-irradiation and repeated surgical resection. Reported response rates to chemotherapy are low and targeted therapies may be one option. We, therefore, investigated signaling pathways that may be active in adenoid cystic cancers. Tissues from the last nine ACC patients resected at the University of Iowa were immunohistochemically stained with antibodies for EGFR, phosphorylated (P) Akt, and P-MAPK in order to molecularly characterize these tumors. An ACC cell line (ACC3) was also characterized by western blot. We found that seven of the nine tumor samples had strong expression of P-Akt and 5/9 had P-MAPK. None of them had EGFR expression. In the ACC3 cell line, similar data was found in that there was P-Akt and P-MAPK but no EGFR expression. We tested the HIV protease inhibitor nelfinavir (NFV) which has been shown to inhibit Akt signaling to see its effect on ACC3 cells. Both P-Akt and P-MAPK were inhibited with NFV in ACC3 cells and this resulted in growth inhibition and clonogenic death. In patients where re-irradiation or further surgery is not an option, a trial of NFV may be warranted.

PMID: 19729990 [PubMed - indexed for MEDLINE]
As(2)O(3) may be a treatment option for adenoid cystic carcinoma of salivary gland.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

As(2)O(3) may be a treatment option for adenoid cystic carcinoma of salivary gland.

Med Hypotheses. 2010 Jul 23;

Authors: Fu ZC, Zhang B, Fu ZJ

Adenoid cystic carcinoma (ACC) is an uncommon tumor of the head and neck that may occur in any salivary gland tissue. Discouraging treatment outcomes may be related to perineural spread, loco regional invasion, and an unusually high incidence of metastatic potential [1]. It presents a number of challenges related to facial nerve management and disease extension into surrounding soft tissue and bony compartments [2]. ACC mostly occurring in the major and minor salivary glands, has some unique characteristics such as slow growth, diffuse invasion, and high incidence of distant metastasis [3]. It is a high malignant carcinoma characterized by intensive local invasion and insidious distant metastasis to the lung at an early stage, which is responsible for a poor long-term survival rate [4]. The main clinical treatment to adenoid cystic carcinoma depended on surgical operation in the past. However, it was not so easy to completely excise adenoid cystic carcinoma which resulting in the residual of tumor cells. Therefore, radiotherapy was often used after the operation. Radiotherapy alone cannot achieve the goal of radical cure, but operation combined with radiotherapy can evidently reduce the post-operative recurrence rate and increase the survival rate. Adenoid cystic carcinoma is not sensitive to conventional chemotherapeutics, so it is necessary to explore a new kind of drug which possesses inhibition and killing effects to this tumor. Arsenic trioxide (A(S2)O(3), ATO), a trivalent inorganic arsenite, has been proved to be an effective therapeutic agent against acute promyelocytic leukemia [8]. Numerous reports have revealed that arsenite exerts its therapeutic activity by induction of apoptosis. It also induces apoptosis in a variety of cancer cells over a wide dose range. A(S2)O(3) may become a treatment option for adenoid cystic carcinoma of salivary gland.

PMID: 20656411 [PubMed - as supplied by publisher]
Adenoid cystic carcinoma of the breast in the United States (1977-2006): a population-based cohort study.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Adenoid cystic carcinoma of the breast in the United States (1977-2006): a population-based cohort study.

Breast Cancer Res. 2010 Jul 23;12(4):R54

Authors: Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM

ABSTRACT: INTRODUCTION: Adenoid cystic carcinoma of the breast (breast-ACC) is a rare and special type of basal-like tumor for which scant population-based descriptive data exists. We sought to provide new population-based information on breast-ACC incidence, relative survival, and associated cancer risk in the United States. METHODS: Using data from the Surveillance, Epidemiology and End Results Program, we calculated age-adjusted incidence rates (IRs), IR ratios (IRRs), and relative survival (RS) for breast-ACC, and standardized incidence ratios (SIRs) for other cancers. RESULTS: Overall 338 women (IR=0.92/one-million person-years) were diagnosed with breast-ACC during 1977 to 2006. Blacks had 39% lower IRs than Whites (IRR=0.61, 95%CI=0.37 to 0.96), and IRs remained constant over the 30-year period. Ninety-five percent of cases presented with localized stage (n=320; IR=0.87), and the highest IRs were observed for estrogen receptor (ER)-negative/progesterone receptor (PR)-negative tumors (IR=0.56). Like other typically ER-negative tumors, age-specific IRs increased until midlife then plateaued. Five-, 10-, and 15-year RS was 98.1%, 94.9%, and 91.4%, respectively. The risk of female breast cancer was not increased following (SIR=0.89, 95%CI=0.43 to 1.64) or preceding (SIR=0.71, 95%CI=0.28 to 1.46) breast-ACC. Similarly, no association was observed for breast-ACC and risk of all other cancers combined, solid tumors, or lymphohematopoietic malignancies. CONCLUSIONS: Breast-ACC among women is characterized by ER-negative/PR-negative expression, rare regional lymph node involvement, a favorable prognosis with excellent survival, and absence of associated cancers. These findings reinforce the importance of tailored treatments for breast-ACC and lend credence to the apparent heterogeneity of basal-like breast cancers.

PMID: 20653964 [PubMed - as supplied by publisher]
Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review.

Head Neck. 2010 Jul 22;

Authors: Papaspyrou G, Hoch S, Rinaldo A, Rodrigo JP, Takes RP, van Herpen C, Werner JA, Ferlito A

Adenoid cystic carcinoma (ACC) is an uncommon tumor usually arising in the head and neck region, mainly in the salivary glands. It demonstrates an indolent prolonged course and is characterized by perineural invasion. Primary treatment of local and locoregional disease consists mainly of surgery and/or irradiation. During follow-up these patients frequently develop local recurrences and distant metastases, especially in the lung, although long-term survival is possible. The role of chemotherapy in ACC is limited, and studies with only a limited number of patients are performed. In this article we review the literature on chemotherapy regimens, including monotherapy and combination chemotherapy schedules, as well as the new targeted therapies. (c) 2010 Wiley Periodicals, Inc. Head Neck, 2010.

PMID: 20652885 [PubMed - as supplied by publisher]
Sublingual gland tumors: Clinical, pathologic, and therapeutic analysis of 13 patients treated in a single institution.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Sublingual gland tumors: Clinical, pathologic, and therapeutic analysis of 13 patients treated in a single institution.

Head Neck. 2010 Jul 19;

Authors: Zdanowski R, Dias FL, Barbosa MM, Lima RA, Faria PA, Castro AL, Souza KC

BACKGROUND.: Sublingual gland tumors are rare, although frequently malignant. This study describes the clinicopathologic features and treatment results and reviews the literature. METHODS.: Thirteen cases treated between 1996 and 2007 were reviewed with interest on clinical, pathologic, and therapeutic information. Survival data were calculated by the Kaplan-Meier method. RESULTS.: Malignancies represented 92.3% of cases. Adenoid cystic carcinoma was the most common malignant type (66.7%). Most patients (83.3%) presented in advanced pathologic TNM stages (III or IV). All cases underwent surgical treatment. Neck dissection was performed in 69.2% with no metastases detected. Ten patients (83.3%) had adjuvant radiotherapy. Distant metastases occurred in 3 patients (25%). The 5-year overall and disease-free survival rates were 78.7% and 87.5%, respectively. CONCLUSIONS.: Tumors of the sublingual gland are rare and are usually malignant. Radical surgery and adjuvant radiotherapy seems to offer adequate local and regional control. Unlike distant failure, local recurrence and regional metastases are not common. (c) 2010 Wiley Periodicals, Inc. Head Neck, 2010.

PMID: 20645286 [PubMed - as supplied by publisher]
Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis.

Oral Oncol. 2010 Jul 14;

Authors: Ota T, Ota K, Jono H, Fujimori H, Ueda M, Shinriki S, Sueyoshi T, Shinohara M, Ando Y

The aims of this study were to investigate midkine (MK) expression patterns in salivary gland tumors (SGTs) and to evaluate the correlation between MK expression and the degree of malignancy. We performed immunohistochemistry to examine MK expression in specimens of adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), and pleomorphic adenoma (PA). In addition, we performed immunohistochemistry for CD31 and measured microvessel density (MVD), which is an indicator of angiogenesis. Immunohistochemistry showed that MK protein expression was significantly higher in specimens of malignant SGTs (ACC [P<0.01] and MEC [P<0.001]) than in benign SGT (PA) samples. Furthermore, MVD values tended to be higher in cases that exhibited high expression of MK, which indicated a significant correlation between the degree of MK expression and MVD (P<0.001). These results suggest that MK may play important roles in malignant transformation and tumor angiogenesis in SGTs.

PMID: 20637680 [PubMed - as supplied by publisher]
[Role of Survivin gene on the apoptosis of adenoid cystic carcinoma-2 cells induced by arsenic trioxide]

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

[Role of Survivin gene on the apoptosis of adenoid cystic carcinoma-2 cells induced by arsenic trioxide]

Hua Xi Kou Qiang Yi Xue Za Zhi. 2010 Jun;28(3):246-9

Authors: Zhang B, Mu HB, Xu XG, Liu W, Hu NR

OBJECTIVE: To investigate the proliferation effects of arsenic trioxide (As2O3) on salivary adenoid cystic carcinoma-2 (ACC-2) cells in vitro and to study the role of Survivin on the apoptosis of ACC-2 induced by As2O3. METHODS: ACC-2 cells were treated with different concentration of As2O3 for different time. The inhibitory effects on cell's viability were assayed with methyl thiazolyl tetrazolium (MTT) test. Apoptosis was determined by flow cytometry. The expression of Survivin mRNA and protein were investigated by reverse transcription-polymerase chain raction (RT-PCR) and Western blot analysis respectively. RESULTS: Cell viability after As2O3 treatment was markedly suppressed and exhibited as a dose- and time-dependent pattern. The apoptotic index showed the similar trend. The results of RT-PCR revealed gene expression of Survivin was suppressed significantly. Through Western blot analysis, a negative correlation between concentration and amount of protein product of Survivin was determined. CONCLUSION: As2O3 might markedly suppressed ACC-2 cell's viability in vitro. The inhibition of Survivin gene expression may play a critical role on ACC-2 cell apoptosis induced by As2O3.

PMID: 20635649 [PubMed - in process]
[Effect of Matrine on cell cycle and human telomerase reverse transcriptase of human salivary adenoid cystic carcinoma]

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

[Effect of Matrine on cell cycle and human telomerase reverse transcriptase of human salivary adenoid cystic carcinoma]

Hua Xi Kou Qiang Yi Xue Za Zhi. 2010 Jun;28(3):234-6, 240

Authors: Zhao JF, Xie WH, Li XM, Chen WT, Sun ML, Fang Z, Sun Q

OBJECTIVE: To investigate the effect of the traditional Chinese medicine Matrine on cell cycle and human telomerase reverse transcriptase (hTERT) of human ACC-M cell lines. METHODS: Different concentrations of Matrine were used in the medium of ACC-M cells. Change of cell cycle were detected by flow cytometry after ACC-M cell were cultivated with different concentrations Matrine (0.25, 0.50, 0.75, 1.00 mg x mL(-1)). Expression of hTERT was investigated by reverse transcription-polymerase chain reaction (RT-PCR) and indirect immunofluorescene and flow cytometry quantitative analysis. RESULTS: Matrine caused obviously the GdG1 phase block and inhibited proliferation of ACC-M cells. At same time, this effect was positive correlation to Matrine concentration and treat time. Matrine can inhibit the expression of hTERT mRNA and protein. CONCLUSION: Matrine can obviously inhibit cell cycle and down-regulate expression of hTERT. Inhibition of cell cycle is possible correlation with down-regulation expression of hTERT.

PMID: 20635646 [PubMed - in process]
Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells.

Anticancer Drugs. 2010 Aug;21(7):678-86

Authors: Zhang S, Wang XL, Gan YH, Li SL

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, originally developed for lowering cholesterol. Statins also have pleiotropic effects, independent of cholesterol-lowering effects, including induction of apoptosis in various cell lines. However, the mechanism underlying statin-induced apoptosis is still not fully understood. This study aims to explore the proapoptotic effects and underlying mechanisms of statins on human salivary adenoid cystic carcinoma (SACC). Exposure of SACC cells to mevastatin resulted in cell growth inhibition and apoptosis in a dose-dependent manner, accompanied by the release of cytochrome c and cleavage of caspase-3. A remarkable decrease in phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and increase in phosphorylation of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated kinase were observed. Furthermore, the JNK-specific inhibitor SP600125, but not the p38-specific inhibitor SB203580, abolished mevastatin-induced cell growth inhibition and apoptosis in SACC cells. This was supported by results in which the JNK inhibitor efficiently blocked mevastatin-induced JNK phosphorylation, but not p38 phosphorylation, and further decreased mevastatin-induced phosphorylation of ERK1/2. Taken together, the results suggest that the JNK pathway was required for mevastatin-induced cell growth inhibition and apoptosis in SACC cells. Statins could be potential anticancer agents for SACC chemotherapy.

PMID: 20629200 [PubMed - in process]
Survival in oral cavity minor salivary gland carcinoma.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Survival in oral cavity minor salivary gland carcinoma.

Otolaryngol Head Neck Surg. 2010 Jul;143(1):122-6

Authors: Kakarala K, Bhattacharyya N

OBJECTIVE: To describe the epidemiology and comparative survival for minor salivary gland cancer of the oral cavity. STUDY DESIGN: Historical cohort study. SETTING: Academic medical center. SUBJECTS AND METHODS: Cases of minor salivary gland cancer of the oral cavity were extracted from the Surveillance, Epidemiology, and End Results database (1988-2005) and staged. Kaplan-Meier survivals were compared according to histology as well as T stage and N stage. A Cox proportional hazards model incorporating histology, T stage, N stage, age, and sex was analyzed. RESULTS: A total of 639 salivary gland cancers of the oral cavity (55% female; mean age, 56 years) were identified with complete staging information, consisting of 318 mucoepidermoid, 169 adenoid cystic, 139 adenocarcinoma, and 14 acinic cell cancers. The hard palate and gums were the most common subsites involved (87.6%), followed by lip (7.2%) and tongue (5.2%). At presentation, T1 and T4 tumors predominated (42.6% and 35.2%, respectively); 93.4 percent were N0. Overall mean survival (months) was 157.9 and was similar across histologic subtypes: mucoepidermoid (172.4), adenoid cystic (141.4), acinic cell (138.7), and adenocarcinoma (147.2). Survival for low- and intermediate-grade mucoepidermoid carcinoma (171.0 and 182.3, respectively) was better than survival for high-grade mucoepidermoid carcinoma (50.3, P < 0.001). On multivariate analysis, N stage (P < 0.001) was the most powerful predictor of survival, along with T stage (P = 0.013), age (P < 0.001), and sex (P < 0.001). CONCLUSION: T stage and N stage are the most powerful predictors of survival in minor salivary gland carcinoma of the oral cavity. With the exception of high-grade mucoepidermoid carcinoma, survival for these lesions is generally favorable.

PMID: 20620630 [PubMed - in process]
Tender tumor of the scalp: clinicopathologic challenge. Primary cutaneous adenoid cystic carcinoma.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Tender tumor of the scalp: clinicopathologic challenge. Primary cutaneous adenoid cystic carcinoma.

Int J Dermatol. 2010 Jun;49(6):605-7

Authors: Torres T, Caetano M, Alves R, Horta M, Selores M

PMID: 20618463 [PubMed - in process]
Dermal cylindroma of the scalp (turban tumour) and subjacent calvarian defects.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Dermal cylindroma of the scalp (turban tumour) and subjacent calvarian defects.

Anticancer Res. 2010 May;30(5):1793-7

Authors: Friedrich RE

This case report describes the diagnosis and therapy of a patient with a 40-year history of multiple potato-like tumours growing in the head and neck region. The tumour proved to be a cylindroma, associated with calvarian defects. Further facial tumours were diagnosed as trichoepitheliomas. This association of findings was pathognomonic for Brooke-Spiegler's syndrome. Complete work-up of the resection specimen excluded any malignant transformation of the tumour. A long lasting history of cylindroma and evidence for bone destruction, not associated with a malignant transformation, is extremely rare in Brooke-Spiegler's syndrome.

PMID: 20592381 [PubMed - indexed for MEDLINE]
Human papillomavirus-associated squamous cell carcinoma of the upper aerodigestive tract.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Human papillomavirus-associated squamous cell carcinoma of the upper aerodigestive tract.

Am J Surg Pathol. 2010 Jul;34(7):e15-24

Authors: Stelow EB, Jo VY, Stoler MH, Mills SE

The association of human papillomavirus with the development of head and neck squamous cell carcinomas has been better elucidated over the past 20 years. In this review article, we examine the role of the virus in the development of these tumors. We discuss the clinical and pathologic features of human papillomavirus-associated squamous cell carcinomas of the head and neck. Immunohistochemical findings and those of other ancillary techniques are also reviewed. We further review the prognosis and treatment of these tumors. Finally, a detailed discussion is provided regarding the differential diagnosis that must be considered when confronting these squamous neoplasms.

PMID: 20534998 [PubMed - indexed for MEDLINE]
Unknown: A woman with an erythematous nodule on the scalp.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Unknown: A woman with an erythematous nodule on the scalp.

Dermatol Online J. 2010;16(4):12

Authors: Aneiros-Fernandez J, Husein-ElAhmed H, Arias-Santiago S, Nicolae A, O'Valle-Ravassa F

A 77-year-old healthy woman presented with an isolated exophytic lesion of the scalp for 4 years, which had grown progressively. On exam, there was a 4 cm, firm erythematous and lobulated tumor with telangiectasias on the scalp. The rest of her cutaneous exam was normal. No lymphadenopathy was appreciated. A solitary cylindroma was diagnosed by biopsy.

PMID: 20409419 [PubMed - indexed for MEDLINE]
Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome.

Am J Dermatopathol. 2010 May;32(3):215-21

Authors: Kazakov DV, Grossmann P, Spagnolo DV, Vanecek T, Vazmitel M, Kacerovska D, Zelger B, Calonje E, Michal M

We performed immunohistochemical assessment of p53 expression and TP53 mutational analysis of 15 malignant neoplasms arising from preexisting benign cylindroma, spiradenoma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome. At least weak and focal p53 positivity was present in 13 of the 15 lesions. Successful PCR and sequencing were possible in 12 of the 15 cases. In one case only there were 2 p53 mutations, one being a c.673-1G>A splice-site mutation in the 3'-end of intron 6 (position--g.15289G>A, contig gb.AY838696.1) and the second being a c.743G>A (p.R248Q) mutation in exon 7 (position--15360G>A, contig gb.AY838696.1). Single nucleotide polymorphisms were detected in all 12 malignant cases analyzed. As a control group, we included 12 randomly selected sporadic cases of spiradenoma (n = 5), cylindroma (n = 4), and spiradenocylindroma (n = 3). None of the 12 benign control group cases harbored a TP53 mutation, whereas all 12 demonstrated single nucleotide polymorphisms identical to those detected in the malignant tumor group. Immunohistochemically, 1 cylindroma and 2 spiradenomas demonstrated weak and focal p53 positivity. In conclusion, we found a fairly high rate of p53 expression in malignant neoplasms arising from preexisting benign spiradenomas, cylindromas, and spiradenocylindromas. However, the mutation rate of TP53 was low. Whereas immunostaining for p53 has been suggested as an adjunct tool to differentiate benign spiradenoma, cylindroma, and spiradenocylindroma from their malignant counterparts, its utility is limited by its heterogeneous pattern of expression, especially the sometimes lack of staining in clearly malignant areas and the occurrence of focal, weak positivity in the benign residua or in unequivocally benign neoplasms.

PMID: 20075707 [PubMed - indexed for MEDLINE]
Immunohistochemical analysis of P(53) and bcl-2 in benign and malignant salivary glands tumors.

Fetched: August 4th, 2010, 9:26am CDT

Related Articles

Immunohistochemical analysis of P(53) and bcl-2 in benign and malignant salivary glands tumors.

J Oral Pathol Med. 2010 Jan;39(1):48-55

Authors: Al-Rawi NH, Omer H, Al Kawas S

BACKGROUND: Salivary glands tumors are relatively uncommon neoplasm with widely variable histopathologic and biologic characteristics. Alteration in some proto-oncogenes and tumor suppressor genes may lead to the development and progression of these tumors. AIMS: The purpose of this study was to analyze the immunohistochemical expression of P(53) and bcl-2 in some salivary gland tumors in relation to tumor size, histologic grade, and extent of invasion. Setting and design: The sample consisted of 22 formalin-fixed paraffin embedded blocks of benign and malignant salivary glands tumors. MATERIAL AND METHOD: P(53) and bcl-2 immunoreactivity was semi-quantitatively evaluated in at least 1000 cells examined under the microscope at 40x magnification and recorded as percentage of P(53) or bcl-2 positive tumor cells over the total number of cells examined in the same area. Percentage scores were subsequently categorized using the 5% cut-off point for positive staining. RESULTS AND CONCLUSION: Pleomorphic adenoma (PA) showed negative expression of P(53) and bcl-2 in 70% of cases, whereas all malignant salivary glands tumors were positive for P(53) and bcl-2. P(53) positive/bcl-2 positive immunostaining reaction was week in small size PA and was totally absent in larger lesions. However, all malignant tumors expressed P(53), with the highest record in low-grade adenocarcinoma (76%) and the lowest score was observed in both low-grade carcinoma in PA and adenocystic carcinoma. bcl-2 immunostaining was also assessed, the highest recorded score was in high-grade adeno cystic carcinoma (90%) and the lowest in both low-grade carcinoma ex-PA and low-grade cystic mucoepidermoid carcinoma (3%). P(53)/bcl-2 immunostaining reactivity could be helpful in demonstrating salivary glands tumor behavior in terms of progression and extent of invasion.

PMID: 19761475 [PubMed - indexed for MEDLINE]
Primary peripheral pulmonary adenoid cystic carcinoma: Report of a case diagnosed by fine needle aspiration cytology.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Primary peripheral pulmonary adenoid cystic carcinoma: Report of a case diagnosed by fine needle aspiration cytology.

Diagn Cytopathol. 2010 Jul 6;

Authors: Chon SH, Park YW, Oh YH, Shinn SH

Adenoid cystic carcinoma (ACC) arising from anatomic sites other than the salivary gland is rare and those occurring in the lung are extremely rare. When arising from the lung, the tumor generally arises from extrapulmonary bronchi, originating from bronchial glands. Primary ACC of the lung located peripherally within lung parenchyme is an even rarer event. To the best of our knowledge, this is the first case of primary peripheral pulmonary ACC preoperatively diagnosed by fine needle aspiration cytology (FNAC). We report a case of primary peripheral ACC of the anterior segment of the right upper lobe in a 46-year-old woman diagnosed by FNAC and a brief review of the literature. Diagn. Cytopathol. 2010. (c) 2010 Wiley-Liss, Inc.

PMID: 20607807 [PubMed - as supplied by publisher]
Clinicopathologic characteristics of 12 patients with vulvar sweat gland carcinoma.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Clinicopathologic characteristics of 12 patients with vulvar sweat gland carcinoma.

Int J Gynecol Cancer. 2010 Jul;20(5):874-8

Authors: Hou JL, Wu LY, Zhang HT, Lv NN, Huang Y, Yu GZ

OBJECTIVES:: The aim of this article was to evaluate the clinical and pathologic characteristics, therapy, and prognostic factors of vulvar sweat gland carcinoma. MATERIALS:: Clinical and pathologic data for 12 patients with vulvar sweat gland carcinoma treated at our institution from January 1958 to April 2009 were retrospectively analyzed. Of the 12 cases, 7 cases were vulvar sweat gland carcinoma, 3 cases were vulvar Paget disease with underlying sweat gland adenocarcinoma, 1 case was vulvar apocrine adenocarcinoma, and 1 case was adenoid cystic carcinoma of the vulvar sweat gland. Two patients were treated with simple vulvar tumor excision at other medical institutions without adjuvant therapy. Among the other 10 patients, 6 underwent radical vulvectomy; 3, wide local excision of the vulva; and 1, a simple vulvectomy. For 5 of the 12 patients, bilateral or unilateral inguinal lymph nodes excision and biopsy were performed. For 1 patient with bulky inguinal lymph nodes, only a biopsy was performed, and the patient received radiotherapy after vulvar surgery. RESULTS:: A follow-up for 11 patients was conducted until death or April 1, 2009. Five of the 11 patients had recurrences after primary treatment. For 2 of these patients, recurrence was local 6 and 48 months after treatment. For 3 patients, distant metastasis was found 18, 5, and 31 months after surgery at our institution. Five of 11 patients died, 1 of whom died of irrelevant disease and 4 of tumor progression. The total survival periods of the 4 patients who died of tumor progression were 24, 36, 44, and 203 months. The other 6 patients have survived for more than 5 years without local failure. In total, there are 7 patients who have survived for 5 years or more. CONCLUSIONS:: Vulvar sweat gland carcinoma is a very rare entity. Surgery is the primary treatment modality, and the function of radiotherapy and chemotherapy is uncertain. The vulvar tumor size and inguinal lymph nodes metastasis will influence the prognosis, with pathologic differentiation and surgical margin status being the probable prognostics factors.

PMID: 20606537 [PubMed - in process]
The treatment of sublingual gland tumours.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

The treatment of sublingual gland tumours.

Int J Oral Maxillofac Surg. 2010 Jun 2;

Authors: Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q

This study assessed the clinical and histological features and therapeutic efficacy of 25 cases of sublingual gland tumours from 1998 to 2008. There were 17 female patients and 8 male, the ratio of females to males was 2.1:1. The mean age was 48.6 years. 4 cases were benign tumours (16%). 21 cases were malignant sublingual gland tumours (84%) and of these, 18 were adenoid cystic carcinoma (86%). Adenoid cystic carcinoma was mainly of the histological type, and the other histological classifications included mucoepidermoid carcinoma, pleomorphic adenoma, myoepithelioma, oncocytoma and polymorphous low-grade adenocarcinoma. Sublingual gland tumours are rare and most are malignant. For malignant sublingual gland tumours, early diagnosis and aggressive surgical treatment, especially for tumours with nerve involvement, is the key to improving prognosis. Free radial forearm flap or pectoralis major myocutaneous flap are appropriate methods for mouth floor reconstruction. For benign sublingual gland tumours, the resection of tumour and sublingual gland is the preferred treatment.

PMID: 20605409 [PubMed - as supplied by publisher]
A report of laryngeal adenocystic carcinoma metastatic to the spleen and the role of splenectomy in the management of metastatic disease: a case report.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

A report of laryngeal adenocystic carcinoma metastatic to the spleen and the role of splenectomy in the management of metastatic disease: a case report.

J Med Case Reports. 2010 Jul 6;4(1):207

Authors: Murray BW, Lyons LC, Mancino A, Huerta S

ABSTRACT: INTRODUCTION: Adenoid cystic carcinoma (ACC) of the larynx is a rare malignancy characterized by an indolent course and late pulmonary metastases. Metastases from the larynx to the spleen are an unusual event. In the present report, we discuss a patient with ACC of the larynx metastatic to the spleen. A review of the literature did not yield any other such incidents. We review the clinical presentation and course of ACC as well as the role of splenectomy for metastases. Case Presentation: We present a case of laryngeal adenoid cystic carcinoma in a 26 year-old caucasian male treated with total laryngectomy and ionizing radiation. He initially developed asynchronous pulmonary metastases, which were resected. The patient subsequently presented with a symptomatic splenic lesion consistent with metastatic disease, for which he underwent laparoscopic splenectomy. CONCLUSION: Splenectomy might be indicated for isolated metastases. A splenectomy effectively addresses symptoms and serves as a cytoreduction modality.

PMID: 20604942 [PubMed - as supplied by publisher]
Salivary gland tumor: a review of 599 cases in a Brazilian population.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Salivary gland tumor: a review of 599 cases in a Brazilian population.

Head Neck Pathol. 2009 Dec;3(4):271-5

Authors: de Oliveira FA, Duarte EC, Taveira CT, MÃ¡ximo AA, de Aquino EC, Alencar Rde C, Vencio EF

Salivary gland tumors consist of a group of heterogeneous lesions with complex clinicopathological characteristics and distinct biological behaviors. Worldwide series show a contrast in the relative incidence of salivary gland tumors, with some discrepancies in clinicopathological data. The main aim of this study was to describe demographic characteristics of 599 cases in a population from Central Brazil over a 10-year period and compare these with other epidemiological studies. Benign tumors represented 78.3% of the cases. Women were the most affected (61%) and the male:female ratio was 1:1.6. Parotid gland tumors were the most frequent (68.5% of cases) and patient age ranged from 1 to 88 years-old (median of 45 years old). The most frequent tumors were pleomorphic adenomas (68.4%) and benign tumors were significantly more frequent in the parotid (75.9%), while malignant tumors were more frequent in the minor salivary glands (40%) (P < 0.05). In conclusion, women and the parotid gland were the most affected and pleomorphic adenoma was the most frequent lesion, followed by adenoid cystic carcinoma and Warthin's tumor.

PMID: 20596844 [PubMed - in process]
Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma.

Oncol Rep. 2010 Aug;24(2):363-8

Authors: Ding LC, She L, Zheng DL, Huang QL, Wang JF, Zheng FF, Lu YG

The Notch signaling pathway is important for cell-cell communication; it is involved in gene regulation mechanisms that control multiple cell differentiation processes during embryonic and adult life. Notch is present in all metazoans, and vertebrates possess four different Notch receptors: Notch-1, Notch-2, Notch-3, and Notch-4. The aim of the present study was to identify the role of Notch protein in the metastasis of salivary adenoid cystic carcinoma (SACC). Real-time PCR results showed that Notch-1, Notch-2, and Notch-4 were upregulated in the highly metastatic SACC cell line ACC-M, compared to ACC-2, a SACC cell line with low metastatic ability. Knockdown of Notch-4 by small interfering RNA efficiently inhibited the invasion of ACC-M cells. Notch-4 expression was significantly higher in the clinical samples with metastasis and recurrence compared to that in control (p<0.05), shown by immunohistochemistry analysis. These results indicate that Notch-4 may play an important role in SACC metastasis.

PMID: 20596622 [PubMed - in process]
Adjuvant radiation therapy is associated with improved survival for adenoid cystic carcinoma of the breast.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Adjuvant radiation therapy is associated with improved survival for adenoid cystic carcinoma of the breast.

J Surg Oncol. 2010 Jun 29;

Authors: Coates JM, Martinez SR, Bold RJ, Chen SL

BACKGROUND: The role of adjuvant radiation therapy (RT) for adenoid cystic carcinoma (ACC) of the breast remains unclear. MATERIALS AND METHODS: We queried the Surveillance, Epidemiology, and End Results database for patients with breast ACC resected between 1988 and 2005, and divided patients based on the receipt of RT. Univariate and multivariate survival comparisons were made for overall and disease-specific survival. RESULTS: Three hundred seventy six patients met criteria for inclusion. Demographics and staging were similar between groups. Univariate analysis revealed an absolute overall and cause-specific survival benefit of 21% and 7% at 10 years (P = 0.005 and P = 0.12 respectively). In the multivariate analysis, RT was a significant predictor of overall and cause-specific survival with hazard ratios of 0.44 (95% Confidence interval (CI) = 0.22-0.88) and 0.1 (95% CI: 0.01-0.88), respectively. CONCLUSIONS: RT after local surgical therapy for ACC of the breast improved both cause-specific and overall survival. Use of RT in this rare tumor should be considered in patients otherwise eligible for RT. J. Surg. Oncol. (c) 2010 Wiley-Liss, Inc.

PMID: 20589709 [PubMed - as supplied by publisher]
Spontaneous regression of thoracic malignancies.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Spontaneous regression of thoracic malignancies.

Respir Med. 2010 May 22;

Authors: Kumar T, Patel N, Talwar A

BACKGROUND: Clinicians are frequently questioned by patients about the possibility of spontaneous regression of tumors. Although there are many reports and a few case series documenting spontaneous regression, there is concern that these cases may not represent true regression. Using specific criteria, we attempted to determine the incidence and types of thoracic malignancy most likely to regress spontaneously. METHODS: We used a PubMed search of the phrase "spontaneous regression of thoracic lesions" reported from 1951 to December 2008. Using a modified Everson and Cole criterion we developed to define spontaneous regression, this search was refined for true spontaneous regression of primary and metastatic thoracic malignancies. RESULTS: Only 5 cases in the literature involved spontaneous regression of a primary thoracic malignancy. These include pleural mesothelioma, primary lung cancer and adenoid cystic carcinoma. 71 cases involved true spontaneous regression of metastatic thoracic neoplasms, of which 5 cases showed regression of the primary extrapulmonary tumors along with the pulmonary metastasis. Thoracic metastasis from renal cell carcinoma was the most common malignancy found to regress spontaneously. CONCLUSION: Spontaneous regression of primary thoracic malignancy is rare. Renal cell carcinoma accounts for most reported cases.

PMID: 20580882 [PubMed - as supplied by publisher]
New mutation in the CYLD gene within a family with Brooke-Spiegler syndrome.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

New mutation in the CYLD gene within a family with Brooke-Spiegler syndrome.

J Dtsch Dermatol Ges. 2010 Feb;8(2):99-101

Authors: Scholz IM, NÃ¼mann A, Froster UG, Helmbold P, Enk AH, NÃ¤her H

Brooke-Spiegler syndrome is a rare, autosomal dominant disease characterized by multiple skin appendage tumors caused by various mutations in the CYLD gene on chromosome 16q12-q13. We describe a family, in which we performed a molecular-genetic examination and found a new mutation in exon 19 in the CYLD gene leading to a frameshift. It is important to be aware of this syndrome and its pathogenesis as its phenotypic features can vary so that apparently different diseases are caused by the same genetic defect. In addition, there may be malignant transformation of the generally benign tumors, so that a timely diagnosis is essential for appropriate monitoring and therapy.

PMID: 20151946 [PubMed - indexed for MEDLINE]
Cylindroma of the external auditory canal: histopathology diagnostic.

Fetched: July 11th, 2010, 1:34pm CDT

Related Articles

Cylindroma of the external auditory canal: histopathology diagnostic.

Otol Neurotol. 2010 Apr;31(3):546-7

Authors: Navarro Paule Mdel P, Fernandez-Gomez FJ, Amores Llorent A, Albaladejo Devis I, Piqueras Perez F

PMID: 19503014 [PubMed - indexed for MEDLINE]
Photodynamic therapy of head and neck cancers.

Fetched: June 26th, 2010, 9:50am CDT

Related Articles

Photodynamic therapy of head and neck cancers.

Methods Mol Biol. 2010;635:281-93

Authors: Biel MA

Over 1,500 patients have been treated with PDT using Photofrin, HPD, ALA, or Foscan for head and neck cancers. These patients include a mixture of presentations including primary, recurrent, and metastatic lesions. The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma. Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers. Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT. Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment. Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up. Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck. It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.

PMID: 20552353 [PubMed - in process]
Occult tracheal tumour detected by lung function tests.

Fetched: June 26th, 2010, 9:50am CDT

Related Articles

Occult tracheal tumour detected by lung function tests.

Clin Respir J. 2009 Jan;3(1):59-61

Authors: Mustonen T, SovijÃ¤rvi AR, PiirilÃ¤ P

PMID: 20298375 [PubMed - indexed for MEDLINE]
Retrospective analysis of intra-oral salivary gland tumours in ibadan, Nigeria.

Fetched: June 15th, 2010, 3:51pm CDT

Related Articles

Retrospective analysis of intra-oral salivary gland tumours in ibadan, Nigeria.

West Afr J Med. 2010 Mar-Apr;29(2):98-103

Authors: Adeyemi BF, Ogun GO, Akang EE

BACKGROUND: Salivary gland neoplasms constitute an important group of intraoral tumours, with their malignant histological types being the second most frequently diagnosed intraoral malignancy. The incidence as well as the anatomical distribution of this heterogeneous group of neoplasms varies from one racial group and geographical location to the other. However, studies from Africa on intraoral salivary gland neoplasms are relatively sparse in the medical literature. OBJECTIVE: To report the frequency and anatomical distribution of the various histological types of minor salivary gland neoplasms diagnosed at the University College Hospital, Ibadan and to provide data for comparison with other epidemiological findings in different geographic locations. METHODS: A retrospective study of intraoral salivary gland neoplasms diagnosed at the University Teaching Hospital, Ibadan between January I991- December 2007. Included in the study were charts of patients with minor salivary glands in the mouth. Information obtained about each patient included age, sex, tumour location and histological classification based on the 1991 WHO recommendations. RESULTS: Of a total of 309 neoplasms of salivary gland origin, 92 were from the intra-oral minor salivary glands constituting 4.5% of head and neck neoplasm. There was no significant gender predilection. Fifty-seven (62%) cases were malignant, while 35 (38%) were benign. The most frequently diagnosed tumour was adenoid cystic carcinoma 35(38%), followed by pleomorphic adenoma 30(32.6%). About 73% of the salivary gland neoplasms affected the palate, followed by the buccal mucosa (16.3%). Patients with malignant neoplasms were about 10 years older than those with benign tumours (p=0.012). CONCLUSION: A large proportion of intraoral salivary gland neoplasms are malignant, the most frequently affected site being the palate.

PMID: 20544634 [PubMed - in process]
[Application of pectoralis major myocutaneous flap in repair of defect caused by resection of tonsillar cancer]

Fetched: June 15th, 2010, 3:51pm CDT

Related Articles

[Application of pectoralis major myocutaneous flap in repair of defect caused by resection of tonsillar cancer]

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2010 May;24(5):556-8

Authors: Ma S, Han Y, Wang W, Zhang M, Wang W, Zhou L

OBJECTIVE: To discuss and evalue the effects and the advantages of pectoralis major myocutaneous flap in repair of defect caused by resection of tonsillar cancer. METHODS: The data were retrospectively summarized from 10 patients with recurrent tonsillar cancer after radical radiotherapy from January 1998 to December 2005, including 7 cases of squamous cell carcinoma, 2 cases of undifferentiated carcinoma, and 1 case of adenoid cystic carcinoma. There were 8 males and 2 females, aged 43-68 years with an average of 58 years. All cases were classified as stages III and IV before radiotherapy according to staging standard of oropharyngeal cancer (International Union Against Cancer, 1997). The time of relapse was 6-32 months after radiotherapy. Recurrent tonsil cancer invased tongue base, soft palate, posterior wall of pharyngeal, parapharyngeal space, and palate. Tumor size was from 4 cm x 2 cm to 8 cm x 5 cm. Seven cases were accompanied by lymph node metastasis. After carcinoma were completely resected and defects were reconstructed by pectoralis major myocutaneous flap of 7 cm x 5 cm-12 cm x 9 cm. The donor sites were sutured directly. RESULTS: After operation, pectoralis major myocutaneous flap completely survived in 9 cases. Partial necrosis of pectoralis major myocutaneous flap was found in 1 case; after treatment, the necrotic flap remained small pharyngeal defect. Incision at donor site healed by first intention in 10 cases. All patients showed satisfactory functions of respiratory, voice, and swallowing with no complication. Ten patients were followed up 2 years to 5 years and 8 months. The 3-year survival rate was 66.7% (6/9), and the 5-year survival rate was 20.0% (1/5). CONCLUSION: Pectoralis major muscle flap has a high survival rate, which is safe, reliable, easy-to-operate, and can repair larger defect. Pectoralis major myocutaneous flap is an ideal material in repair of defect caused by resection of recurrent tonsillar carcinoma after radiotherapy.

PMID: 20540259 [PubMed - in process]
Neoplasms of the salivary glands in a Turkish adult population.

Fetched: June 15th, 2010, 3:51pm CDT

Related Articles

Neoplasms of the salivary glands in a Turkish adult population.

Med Oral Patol Oral Cir Bucal. 2010 Jun 1;

Authors: Karaa ML, GÃ¶ze F, Ezirganli S, Polat S, Muderris S, Elagoz S

Objective: This retrospective study aimed to investigate the types and distribution of neoplasm of salivary glands in a Turkish population. Study Design: The histological diagnosis records of the Department of Pathology at Cumhuriyet University were reevaluated for 125 patients who were treated for salivary gland tumors from 1987 to 2008. The neoplasms were analyzed for histological diagnosis, age, sex, and site. The histological diagnoses were analyzed according to the 2005 WHO classification. Results: A total of 125 primary salivary gland neoplasms, consisting of 95 (76%) benign and 30 (24%) malignant groups were recorded. The most common major and minor salivary gland sites were the parotid (61.6%) and palatal glands (9.6%), respectively. Pleomorphic adenoma was the most frequent benign tumor followed by Warthin's tumor. Among the malignant group, adenoid cystic carcinoma was the most prevalent. Age for all cases ranged from 16-80 years; mean age was 41.97 years, with a female to male ratio of 1:1.15. Conclusions: Although there were some discrepancies, the characteristics of salivary gland tumors of Turkish patients are in line with those of patients from other countries according to tumor type, tumor site distribution, and age and sex of patients.

PMID: 20526249 [PubMed - as supplied by publisher]
C-kit gene mutations in adenoid cystic carcinoma are rare.

Fetched: June 15th, 2010, 3:51pm CDT

Related Articles

C-kit gene mutations in adenoid cystic carcinoma are rare.

Mod Pathol. 2010 Jun;23(6):905-6; author reply 906-7

Authors: Moskaluk CA, Frierson HF, El-Naggar AK, Futreal PA

PMID: 20514080 [PubMed - in process]
[Clinicopathological characteristics of six patients with adenoid cystic carcinoma of the Bartholin gland.]

Fetched: June 15th, 2010, 3:51pm CDT

Related Articles

[Clinicopathological characteristics of six patients with adenoid cystic carcinoma of the Bartholin gland.]

Zhonghua Zhong Liu Za Zhi. 2010 Apr;32(4):290-3

Authors: Hou JL, Wu LY, Zhang HT, Li N, Yu GZ

OBJECTIVE: To evaluate the clinicopathological characteristics and treatment of adenoid cystic carcinoma of the Bartholin gland. METHODS: The clinicopathological data of six patients with adenoid cystic carcinoma of the Bartholin gland were retrospectively analyzed. The median age was 40.8 years (range 30 to 54 years). Surgery was the primary treatment. Simple vulvar tumor resection was performed in 1 patient. Four cases underwent radical vulvectomy with bilateral inguinal lymph node dissection and 1 case underwent wide local excision of the vulva with bilateral inguinal lymph node biopsy. Two cases with high risk factors received postoperative radiotherapy. RESULTS: All patients had definite pathological diagnosis. Cribriform arrangement of tubules and gland-like elements and infiltration of perineural spaces were two main microscopic features of this type of tumor. The pathological examination after surgery revealed that two patients had positive surgical margins, one had negative margin, 1 adjacent to the tumor and 1 unknown;5 cases had negative inguinal lymph nodes and 1 unknown. All the 6 patients were followed-up. Recurrence developed in 4 cases including 3 with both local recurrence and lung metastasis, and one had lung metastasis only. One patient died of lung matastasis and her total survival period was 135 months. The other 3 recurrent patients survived with tumor and the total survival period was 241, 128 and 103 months, respectively. Two cases without recuccrence survived 8 and 121 months, respectively. CONCLUSION: Adenoid cystic carcinoma of the Bartholin gland is a slow growing but locally very aggressive neoplasm with a high capacity for local recurrence and lung metastasis. Surgery is the most common and useful treatment. Radiation is a choice of treatment for patients with high risk factors after surgery such as positive surgical margin, deep local invasion and infiltration of perineural spaces or for recurrent patients without opportunity of excision.

PMID: 20510082 [PubMed - in process]
Immunophenotypic aspects of cylindroma and nodular hidradenoma.

Fetched: June 15th, 2010, 3:51pm CDT

Related Articles

Immunophenotypic aspects of cylindroma and nodular hidradenoma.

J Eur Acad Dermatol Venereol. 2010 Feb;24(2):178-85

Authors: Canedo T, de Almeida MP, Cuzzi T, Ramos-e-Silva M

BACKGROUND: Some adnexal tumours have many controversies about their histogenesis. OBJECTIVES: To evaluate the eccrine and/or apocrine differentiation phenotype in cases of cylindroma and clear cell hidradenoma with CD15 and p63 antibodies. METHODOLOGY: Slides and blocks of six cases of cylindroma and seven cases of nodular hidradenoma (clear cells) were analyzed by the technique of immunohistochemistry with CD15 and p63 antibodies. RESULTS: In all cases of cylindroma we obtained negative results for CD15 antibody and positive for p63 antibody. In five of seven cases of nodular hidradenoma (clear cell), we could easily observe clear cells between 20% and 50% of tumour cells. In the two other cases, cystic lesions were present and occasional clear cells could be seen. The reaction with CD15 antibody was positive in granular and cytoplasmic pattern in six of seven cases, especially in cells with suggestive clear cytoplasm in lower proportion than this clear cells could be seen in haematoxylin and eosin. The positivity for p63 antibody, nuclear pattern, was observed in six of seven cases, in the major part of tumour cells. In only one case, the positivity was in 20% of cells. Limitation Samples are in small number because these are relatively rare tumours. CONCLUSIONS: The present study suggests eccrine origin for both tumours: cylindroma and clear cell hidradenoma.

PMID: 19796089 [PubMed - indexed for MEDLINE]